Immune thrombocytopenia
Conditions
Interventions
Healthy control group:None
Immune thrombocytopenia group:None
Connective tissue disease group:None
Connective tissue disease with thrombocytopenia group:None
Connective tissue disease complicated with refractory thrombocytopenia group:None
Hematological tumors combined with thrombocytopenia group:None
Sponsors
Department of Rheumatology and Allergy, Xuanwu Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Healthy control group: 1. Age greater than 18 years old 2. Patients without connective tissue disease 3. No thrombocytopenia within 6 months at the time of enrollment (thrombocytopenia greater than 100*109/L) Idiopathic thrombocytopenia group (ITP): 1. Age greater than 18 years old 2. Newly diagnosed patients who meet the diagnostic criteria for ITP 3. Thrombocytopenia<100*109/L, medical history for more than 6 weeks Hematological malignancies with thrombocytopenia group: 1. Age greater than 18 years old 2. Meet the diagnostic criteria for hematologic tumors 3. Thrombocytopenia less than 100*109/L for more than 6 weeks Connective tissue disease with thrombocytopenia: 1. Age greater than 18 years old 2. Meet the diagnostic criteria for ACR or EULAR connective tissue disease 3. Thrombocytopenia<100*109/L, medical history for more than 6 weeks 4. Oral glucocorticoids (10-20mg/day, prednisone or equivalent) stable regimen for 4 weeks =, and the original treatment drug type and dose remain unchanged after enrollment. Connective tissue disease with refractory thrombocytopenia group 1. Age 18 years old or above 2. Meet the diagnostic criteria for ACR or EULAR connective tissue disease 3. Thrombocytopenia <50*109/L, with a medical history of more than 6 months 4. Standardized glucocorticoid treatment for 3 weeks without response or long-term maintenance of hormones exceeding the equivalent dose of more than 5mg; or at least one time of normative glucocorticoids or 1 immunosuppressant treatment after ineffective treatment and relapse after discontinuation of the drug. 5. Patients with connective tissue disease complicated with thrombocytopenia treated with oral sirolimus
Exclusion criteria
Exclusion criteria: 1. Pregnant/lactating; 2. Incomplete baseline data; 3. Combined with severely uncontrolled infected people 4. Intravenous CTX within 6 months of enrollment; Intravenous immunoglobulin or prednisone > 100 mg/day within 3 months; Calcineurin inhibitors (such as tacrolimus or cyclosporine A) for 1 month; 5. Malignant tumors 6. Patients with hepatosplenomegaly 7. Presence of other secondary thrombocytopenia diseases 8. Co-existing active or uncontrolled infections (such as tuberculosis and hepatitis) requiring the use of antibiotics or antiviral drugs; 9. Abnormal laboratory indicators: white blood cell count 1.5 times the upper limit of the laboratory reference range; Total bilirubin or blood lipids (including total cholesterol, triglycerides, low-density lipoprotein) > 2 times the upper limit of the laboratory reference range.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treg cells;Platelet count;Subgroup T;Subgroup B; | — |
Secondary
| Measure | Time frame |
|---|---|
| Alanine aminotransferase;Serum creatinine;Potassium in the blood; | — |
Countries
China
Contacts
Public ContactLi Xuemei
Department of Rheumatology and Allergy, Xuanwu Hospital, Capital Medical University
Outcome results
None listed